Corundum Group’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.4M | Buy |
7,520
+2,391
| +47% | +$444K | 0.62% | 34 |
|
|
2025
Q1 | $1.07M | Sell |
5,129
-4,052
| -44% | -$849K | 0.52% | 47 |
|
|
2024
Q4 | $1.63M | Buy |
9,181
+4,159
| +83% | +$739K | 0.61% | 48 |
|
|
2024
Q3 | $992K | Sell |
5,022
-4,211
| -46% | -$832K | 0.45% | 52 |
|
|
2024
Q2 | $1.58M | Buy |
9,233
+4,367
| +90% | +$749K | 0.62% | 45 |
|
|
2024
Q1 | $886K | Sell |
4,866
-102
| -2% | -$18.6K | 0.43% | 54 |
|
|
2023
Q4 | $770K | Buy |
4,968
+106
| +2% | +$16.4K | 0.39% | 54 |
|
|
2023
Q3 | $725K | Sell |
4,862
-873
| -15% | -$130K | 0.41% | 56 |
|
|
2023
Q2 | $773K | Sell |
5,735
-4,295
| -43% | -$579K | 0.39% | 61 |
|
|
2023
Q1 | $1.6M | Buy |
10,030
+3,526
| +54% | +$562K | 0.76% | 37 |
|
|
2022
Q4 | $1.05M | Buy |
6,504
+120
| +2% | +$19.4K | 0.59% | 43 |
|
|
2022
Q3 | $857K | Buy |
6,384
+898
| +16% | +$121K | 0.54% | 45 |
|
|
2022
Q2 | $840K | Buy |
5,486
+100
| +2% | +$15.3K | 0.57% | 45 |
|
|
2022
Q1 | $873K | Buy |
5,386
+143
| +3% | +$23.2K | 0.81% | 45 |
|
|
2021
Q4 | $710K | Buy |
5,243
+547
| +12% | +$74.1K | 0.46% | 42 |
|
|
2021
Q3 | $507K | Buy |
4,696
+488
| +12% | +$52.7K | 0.38% | 41 |
|
|
2021
Q2 | $474K | Buy |
4,208
+57
| +1% | +$6.42K | 0.31% | 45 |
|
|
2021
Q1 | $449K | Buy |
4,151
+87
| +2% | +$9.41K | 0.35% | 44 |
|
|
2020
Q4 | $435K | Buy |
4,064
+325
| +9% | +$34.8K | 0.36% | 41 |
|
|
2020
Q3 | $327K | Buy |
3,739
+231
| +7% | +$20.2K | 0.32% | 44 |
|
|
2020
Q2 | $344K | Buy |
+3,508
| New | +$344K | 0.41% | 30 |
|